Urticaria laboratory findings: Difference between revisions
Jump to navigation
Jump to search
| Line 23: | Line 23: | ||
|- | |- | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Interleukin 6]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Interleukin 6]] | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Presents [[disease]] activity | ||
______________________________________________ | |||
|- | |- | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Interleukin 1]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Interleukin 1]] | ||
| Line 30: | Line 30: | ||
Such as [[Interleukin 18]] and [[Interleukin 17]] | Such as [[Interleukin 18]] and [[Interleukin 17]] | ||
More studies are required | More studies are required | ||
<br> | |||
______________________________________________ | |||
|- | |- | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Interleukin|Interleukin 23]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Interleukin|Interleukin 23]] | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | An [[Interleukin|Interleukin 23]]/[[Interleukin 17]] axis has been explained in [[pathogenesis]] of [[urticaria]]. | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | An [[Interleukin|Interleukin 23]]/[[Interleukin 17]] axis has been explained in [[pathogenesis]] of [[urticaria]]. | ||
______________________________________________ | |||
|- | |- | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Interleukin 31]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | [[Interleukin 31]] | ||
| style="padding: 0 5px; background: #F5F5F5; text-align: left;" | *Also elevated in other [[inflammation|chronic skin inflammations]] | | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | | ||
*Also elevated in other [[inflammation|chronic skin inflammations]] | |||
*No association to [[disease]] activity | *No association to [[disease]] activity | ||
*[[Omalizumab]] [[treatment]] lead to a remarkable reduction in [[interleukin 31]] response and might be used as a predictor of response to [[omalizumab]] | *[[Omalizumab]] [[treatment]] lead to a remarkable reduction in [[interleukin 31]] response and might be used as a predictor of response to [[omalizumab]] | ||
|- | |- | ||
|} | |} | ||
Revision as of 10:05, 10 January 2021
|
Urticaria Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Urticaria laboratory findings On the Web |
|
American Roentgen Ray Society Images of Urticaria laboratory findings |
|
Risk calculators and risk factors for Urticaria laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Findings
- Autologous serum skin test (ASST) and basophil activation test (BAT) are two tests that are capable of detecting any autoantibodies against IgE for FcεRI.[1][2]
- Although ASST is not a specific test, positive results can determine active disease, mast cells and basophils activation and possible reduction in basophils.
- Interestingly positive autologous serum skin test (ASST) could be related to better prognosis.
- Moreover positive autologous serum skin test (ASST) seems to be related to slower response to omalizumab.
- C-reactive protein (CRP) is also related to disease activity and treatment response in urticaria.[3][4][5]
- It's elevated level is also associated with positive autologous serum skin test (ASST) and elevated levels of erythrocyte sedimentation rate (ESR), leukocytes, neutrophils and IL-6.
- Elevated CRP is related to better response to oral cyclosporine therapy and conversely poor response to antihistamines.
- In contrast to other inflammatory conditions, urticaria patients usually present with lower quantitative level of CRP.
- Interleukins
- Elevated level of IL-6 is related to disease activity in urticaria.[4]
- IL-18, one of the IL-1 family cytokines, has been present in serum specimens of nearly all patients with chronic spontaneous urticaria. Nevertheless more studies required to determine it's exact role in the pathogenesis of this subtype.[6][7]
- The following table is a summary of possible elevated interleukins in urticaria:[7][1][8]
| Interleukins | Explanations |
|---|---|
| Interleukin 6 | Presents disease activity
______________________________________________ |
| Interleukin 1 |
Such as Interleukin 18 and Interleukin 17
More studies are required
|
| Interleukin 23 | An Interleukin 23/Interleukin 17 axis has been explained in pathogenesis of urticaria.
______________________________________________ |
| Interleukin 31 |
|
References
- ↑ 1.0 1.1 Puxeddu I, Petrelli F, Angelotti F, Croia C, Migliorini P (2019). "Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications". J Asthma Allergy. 12: 285–295. doi:10.2147/JAA.S184986. PMC 6759208 Check
|pmc=value (help). PMID 31571935. - ↑ Ye YM, Park JW, Kim SH, Ban GY, Kim JH, Shin YS; et al. (2016). "Prognostic Factors for Chronic Spontaneous Urticaria: A 6-Month Prospective Observational Study". Allergy Asthma Immunol Res. 8 (2): 115–23. doi:10.4168/aair.2016.8.2.115. PMC 4713874. PMID 26739404.
- ↑ Kolkhir P, Altrichter S, Hawro T, Maurer M (2018). "C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria". Allergy. 73 (4): 940–948. doi:10.1111/all.13352. PMID 29130488.
- ↑ 4.0 4.1 Kasperska-Zajac A, Sztylc J, Machura E, Jop G (2011). "Plasma IL-6 concentration correlates with clinical disease activity and serum C-reactive protein concentration in chronic urticaria patients". Clin Exp Allergy. 41 (10): 1386–91. doi:10.1111/j.1365-2222.2011.03789.x. PMID 21645137.
- ↑ Ohtsuka T (2010). "Response to oral cyclosporine therapy and high sensitivity-CRP level in chronic idiopathic urticaria". Int J Dermatol. 49 (5): 579–84. doi:10.1111/j.1365-4632.2010.04384.x. PMID 20534097.
- ↑ Tedeschi A, Lorini M, Suli C, Asero R (2007). "Serum interleukin-18 in patients with chronic ordinary urticaria: association with disease activity". Clin Exp Dermatol. 32 (5): 568–70. doi:10.1111/j.1365-2230.2007.02450.x. PMID 17509061.
- ↑ 7.0 7.1 Puxeddu I, Italiani P, Giungato P, Pratesi F, Panza F, Bartaloni D; et al. (2013). "Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria". Cytokine. 61 (3): 741–3. doi:10.1016/j.cyto.2013.01.015. PMID 23433789.
- ↑ Kolkhir P, André F, Church MK, Maurer M, Metz M (2017). "Potential blood biomarkers in chronic spontaneous urticaria". Clin Exp Allergy. 47 (1): 19–36. doi:10.1111/cea.12870. PMID 27926978.